Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Cardioblate

This article was originally published in The Gray Sheet

Executive Summary

Surgical radiofrequency "pen" system gains FDA market go-ahead for general ablation of cardiac tissue to neutralize "troublesome electrical activity," firm announces Jan. 29. The device incorporates delivery of an electrolytic irrigation solution to cool the outer tissue and allow deeper heat penetration to improve ablation effectiveness, company explains. Medtronic plans to pursue a specific indication for chronic atrial fibrillation with the "Maze" procedure later this year...
Advertisement

Related Content

Medtronic next-gen Cardioblate BP cleared by FDA
Advertisement
UsernamePublicRestriction

Register

MT016056

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel